Safety, efficacy, and PK/PD of a BCMA-targeted CAR-NK cell therapy (LUCAR-B68) in relapsed/refractory multiple myeloma: a phase I study

Cytotherapy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles